Search Results - inflammatory

11 Results Sort By:
Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma)
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma and consists of three subtypes: activated B-cell (ABC), germinal center B-cell (GBC), and primary mediastinal B-cell (PMB). Despite advances in the front-line therapy for DLBCL, approximately one-third of patients will relapse. Substantially worse outcomes...
Published: 8/14/2024   |   Inventor(s): Louis Staudt, Yiban Yang, Federico Bernal
Keywords(s): ABC DLBCL, Activated B Cell-like, Autoimmune, Bernal, CANCER, Diffuse Large B Cell Lymphoma, INFLAMMATORY, Linear Ubiquitin-chain Assembly Complex, LUBAC, NF-κB, Non-Hodgkin’s Lymphoma, Peptide Inhibitor, Staudt, therapeutic
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, TherapeuticArea > Immunology
Customized Telodendrimer Nanocarriers for Targeted Drug Delivery for Disease Treatments
A suite of nanocarrier technologies that provide targeted drug delivery of hydrophobic and hydrophilic drugs to specific disease sites. Background: Delivery of therapeutic and diagnostic compounds is limited by the lack of efficient carriers to improve in vivo stability, selectivity as well as to reduce immunogenicity. Conventional nanocarrier design...
Published: 1/8/2025   |   Inventor(s): Juntao Luo, Dandan Guo, Changying Shi
Keywords(s): #SUNYresearch, affinity alkylating agent, autoimmune, autoimmune disease, bioactivity, biocompatible, biomaterials, chemical formulation, chemistry, cisplatin, combintorial conjugated dendrimer, dendritic drug delivery, drug delivery component, drug formulation, Featured, graft rejection, hydrophilic drug, hydrophobic drug, immune modulating, immunogenicity inflammation, inflammatory, inflammatory, inflammatory, inflammatory, inflammatory response, inflammatory response, intracellular delivery, methotrexate, moieties, nanocarriers, nanomedicine, nanoparticle, nanoparticle drug delivery, nanoparticle-enhanced delivery, nanotherapy, polyethylene glycol, polymyxin, targeted biologics delivery, targeted delivery, targeted drug delivery, targeted therapeutic delivery, targeting drug, Technologies, therapeutic drug, topoisomerase, vitamin E
Category(s): Technology Classifications > Drug Delivery, Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Healthcare, Campus > Upstate Medical University
Customized Telodendrimer Nanocarriers for Targeted Drug Delivery for Disease Treatments
A suite of nanocarrier technologies that provide targeted drug delivery of hydrophobic and hydrophilic drugs to specific disease sites. Background: Delivery of therapeutic and diagnostic compounds is limited by the lack of efficient carriers to improve in vivo stability, selectivity as well as to reduce immunogenicity. Conventional nanocarrier design...
Published: 1/8/2025   |   Inventor(s): Juntao Luo, Dandan Guo, Changying Shi
Keywords(s): #SUNYresearch, affinity alkylating agent, autoimmune, autoimmune disease, bioactivity, biocompatible, biomaterials, chemical formulation, chemistry, cisplatin, combintorial conjugated dendrimer, dendritic drug delivery, drug delivery component, drug formulation, Featured, graft rejection, hydrophilic drug, hydrophobic drug, immune modulating, immunogenicity inflammation, inflammatory, inflammatory, inflammatory, inflammatory, inflammatory response, inflammatory response, intracellular delivery, methotrexate, moieties, nanocarriers, nanomedicine, nanoparticle, nanoparticle drug delivery, nanoparticle-enhanced delivery, nanotherapy, polyethylene glycol, polymyxin, targeted biologics delivery, targeted delivery, targeted drug delivery, targeted therapeutic delivery, targeting drug, Technologies, therapeutic drug, topoisomerase, vitamin E
Category(s): Technology Classifications > Drug Delivery, Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Healthcare, Campus > Upstate Medical University
Customized Telodendrimer Nanocarriers for Targeted Drug Delivery for Disease Treatments
A suite of nanocarrier technologies that provide targeted drug delivery of hydrophobic and hydrophilic drugs to specific disease sites. Background: Delivery of therapeutic and diagnostic compounds is limited by the lack of efficient carriers to improve in vivo stability, selectivity as well as to reduce immunogenicity. Conventional nanocarrier design...
Published: 1/8/2025   |   Inventor(s): Juntao Luo, Dandan Guo, Changying Shi
Keywords(s): #SUNYresearch, affinity alkylating agent, autoimmune, autoimmune disease, bioactivity, biocompatible, biomaterials, chemical formulation, chemistry, cisplatin, combintorial conjugated dendrimer, dendritic drug delivery, drug delivery component, drug formulation, Featured, graft rejection, hydrophilic drug, hydrophobic drug, immune modulating, immunogenicity inflammation, inflammatory, inflammatory, inflammatory, inflammatory, inflammatory response, inflammatory response, intracellular delivery, methotrexate, moieties, nanocarriers, nanomedicine, nanoparticle, nanoparticle drug delivery, nanoparticle-enhanced delivery, nanotherapy, polyethylene glycol, polymyxin, targeted biologics delivery, targeted delivery, targeted drug delivery, targeted therapeutic delivery, targeting drug, Technologies, therapeutic drug, topoisomerase, vitamin E
Category(s): Technology Classifications > Drug Delivery, Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Healthcare, Campus > Upstate Medical University
Customized Telodendrimer Nanocarriers for Targeted Drug Delivery for Disease Treatments
A suite of nanocarrier technologies that provide targeted drug delivery of hydrophobic and hydrophilic drugs to specific disease sites. Background: Delivery of therapeutic and diagnostic compounds is limited by the lack of efficient carriers to improve in vivo stability, selectivity as well as to reduce immunogenicity. Conventional nanocarrier design...
Published: 1/8/2025   |   Inventor(s): Juntao Luo, Dandan Guo, Changying Shi
Keywords(s): #SUNYresearch, affinity alkylating agent, autoimmune, autoimmune disease, bioactivity, biocompatible, biomaterials, chemical formulation, chemistry, cisplatin, combintorial conjugated dendrimer, dendritic drug delivery, drug delivery component, drug formulation, Featured, graft rejection, hydrophilic drug, hydrophobic drug, immune modulating, immunogenicity inflammation, inflammatory, inflammatory, inflammatory, inflammatory, inflammatory response, inflammatory response, intracellular delivery, methotrexate, moieties, nanocarriers, nanomedicine, nanoparticle, nanoparticle drug delivery, nanoparticle-enhanced delivery, nanotherapy, polyethylene glycol, polymyxin, targeted biologics delivery, targeted delivery, targeted drug delivery, targeted therapeutic delivery, targeting drug, Technologies, therapeutic drug, topoisomerase, vitamin E
Category(s): Technology Classifications > Drug Delivery, Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Healthcare, Campus > Upstate Medical University
Methods for Amelioration and Treatment of Pathogen-associated Inflammatory Response
This CDC invention provides methods for preventing or treating inflammatory response-linked, infection induced pathologies, which are mediated by endogenous substance P. Substance P is a naturally-occurring and major pro-inflammatory neuromediator or neuromodulator, and elevated levels of substance P have been implicated in numerous inflammation-associated...
Published: 10/28/2024   |   Inventor(s): Larry Anderson, Deborah Moore, Ralph Tripp
Keywords(s): bronchoilitis, CAUSED, CDC Docket Import, CDC Docket Import CDC Prosecuting, DB3XXX, DB4XXX, DBXXXX, DISEASES, DXXXXX, IB3XXX, Infection, Inflammation, INFLAMMATORY, Methods, nitric oxide, OID-NCIRD-DVD, P, Pain, pain control, Prevention, Pulmonary, RESPONSE, RSV, RSV virus, SUBSTANCE, SUBSTANCE p, treatment, treatment methods, vasodilation, VASODILATOR, VAXXXX, VBXXXX, VDXXXX, VEXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VOXXXX, VPXXXX, WAXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, YBXXXX, YCXXXX
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Ophthalmology, TherapeuticArea > Infectious Disease, TherapeuticArea > Cardiology, TherapeuticArea > Oncology, Application > Consumer Products, Application > Therapeutics, TherapeuticArea > Dental, TherapeuticArea > Endocrinology, Application > Vaccines, ResearchProducts > Antibodies, TherapeuticArea > Immunology, TherapeuticArea > Neurology, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Geriatrics
Modulation of Leucine-rich Repeats and Calponin Homology Domain-containing Protein 4 (Lrch4) Activity for Therapeutic Applications
NIH Inventors have recently discovered a novel Leucine-rich repeat and calponin homology domain-containing protein 4 (Lrch4) in a proteomic screen of the plasma membrane of lipopolysaccharide (LPS)-exposed macrophages. Expression data by RT-PCR revealed that all Lrch family members (1-4) are expressed in macrophages, but only Lrch4 was recruited into...
Published: 10/28/2024   |   Inventor(s): Michael Fessler
Keywords(s): CB6XXX, CBXXXX, CXXXXX, DISEASES, GB1XXX, GBXXXX, GXXXXX, IB3XXX, IBXXXX, INFLAMMATORY, IXXXXX, Lrch4, Sepsis, TARGET, therapeutic
Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology
Muramyl Dipeptide as a Therapeutic Agent for Inflammation
The nucleotide-binding oligomerization domain 2 (NOD2) protein plays a key role in innate immunity as a sensor of muramyl dipeptide (MDP), a breakdown product of bacterial peptidoglycan. Bacterial peptidoglycan promotes the innate immune response through the activation of Toll-like receptor 2 (TLR2), which ultimately provokes inflammation. Activation...
Published: 10/28/2024   |   Inventor(s): Warren Strober
Keywords(s): Autoimmune, AUTOIMMUNE DISEASE, Autoimmune disorder, Autoimmunity, BBXXXX, BCXXXX, BOWEL, Crohn disease; Inflammatory bowel disease 1, Crohn's disease, Dipeptide, IB3XXX, IBD, IBXXXX, IL-12, Inflammation, INFLAMMATORY, inflammatory bowel disease, Inflammatory bowel disease 1, inflammatory disease, INTERLEUKIN, INTERLEUKIN-12, IRF4, IXXXXX, MDP, Muramyl, NOD2, peptidoglycan, TLR, TLR2, Toll-like, Toll-like receptors, Ulcerative Colitis
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics
Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Autoimmune Inflammatory Diseases
Autoimmune inflammatory diseases occur in greater than five percent of the United States population; this disease group includes asthma, multiple sclerosis, rheumatoid arthritis, and lupus. Treatments generally include immunosuppressants or anti-inflammatory drugs, which can have serious side effects; recently, more specific immunomodulatory therapies...
Published: 12/27/2024   |   Inventor(s): Francoise Meylan, Yun-Jeong Song, Richard Siegel
Keywords(s): antibodies, ANTIBODY, ANTI-HUMAN, Anti-mouse, Autoimmune, diagnostic, DR3, IA3XXX, IAXXXX, IB3XXX, IBXXXX, Immunomodulation, immuno-modulator, immunomodulatory, INFLAMMATORY, inflammatory disease, IXXXXX, monoclonal, Monoclonal Antibodies, Monoclonal Antibody, Patent Category - Biotechnology, therapeutic, TL1A, tnf, TNFRSF25, TNFSF15, tumor necrosis factor, USES
Category(s): Application > Research Materials, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Immunology
Novel Genetic Tristetraprolin (TTP) Knock-in Mouse
Tristetraprolin (TTP) is the prototype member of a small family of RNA binding proteins that bind to specific types of AU-rich elements in the 3'UTRs of target mRNAs and promote their rapid turnover. One of the targets destabilized by TTP is Tumor necrosis factor alpha (TNF). TNF has long been a target of anti-inflammatory drug development, in which...
Published: 10/28/2024   |   Inventor(s): Perry Blackshear
Keywords(s): Cells, DISEASES, Increasing, INFLAMMATORY, Listed LPM Reichman as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, THERAPY, TISSUES, Tristetraprolin, TTP, WIXXXX
Category(s): Collaboration Sought > Licensing, Application > Research Materials
1 2